Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This study found that among adults with severe alopecia areata, alopecia totalis, or alopecia universalis, oral tofacitinib was more effective than methotrexate in reducing hair loss over a 12-week period, though long-term safety and efficacy remain unestablished.

This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.

This study found that people with androgenic alopecia, particularly women, are more prone to anxiety and depression, often adopting avoidant coping strategies, which are linked to emotional and psychological impacts rather than clinical severity.

In this study, researchers retrospectively analyzed five children with extensive and refractory alopecia areata treated with mesalazine, observing complete hair regrowth in all patients without side effects, suggesting potential benefits of this treatment combination, though controlled studies are needed for confirmation.

In this study, among postmenopausal women with female androgenetic alopecia, the combination of Pygeum africanum and Serenoa repens extracts at higher doses plus MSM significantly increased total hair growth and hair resistance compared to a lower dose formulation after 16 weeks.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

In this study, combination therapy with cyclosporine and PUVA for severe alopecia areata resulted in a majority of patients showing only fair to poor responses, though some improvements were noted.

This review discusses treatment options for hereditary angioedema and reports no new results; it highlights concerns about androgen side effects and mentions approved alternatives with fewer serious adverse effects.

This open-pilot study found that topical 1% sildenafil did not show significant hair growth in children with alopecia areata, as outcomes seemed due to spontaneous disease regression.

This study found that patients with unresectable melanoma treated with AZD6244 experienced skin reactions, including depigmentation and papulopustular rashes, in patterns similar to those caused by EGFR inhibitors.

This article examines the potential of using oral minoxidil as an adjuvant treatment for patients with severe alopecia areata who do not respond to increased doses of Janus kinase inhibitors, but provides no new clinical results.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This study analyzed social media posts on alopecia areata treatments and found that while most reported perceived improvement, many treatments, particularly dexamethasone, were associated with underlying negative emotions.

This case report describes a drug-related skin eruption following AstraZeneca-Oxford vaccination, which resolved after treatment with oral prednisolone.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

This study reported that 1% bexarotene gel was well tolerated and possibly effective for inducing partial hair regrowth in alopecia areata, but more rigorous trials are needed to confirm its efficacy.

This study found that a data-driven model using XGBoost effectively predicts individualized responses to minoxidil for androgenetic alopecia, outperforming traditional methods in accuracy and reliability.

This study demonstrated that the pharmacokinetic profiles of finasteride and doxazosin remain bioequivalent when administered in combination compared to when each drug is taken alone.